ITEM 3. LEGAL PROCEEDINGS
99
ITEM 4. MINE SAFETY DISCLOSURES
99
PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
100
ITEM 6. [RESERVED]
101
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
102
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
115
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
116
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
141
ITEM 9A. CONTROLS AND PROCEDURES
141
ITEM 9B. OTHER INFORMATION
143
ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
143
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
144
ITEM 11. EXECUTIVE COMPENSATION
144
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
144
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
144
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
144
PART IV
ITEM 15. EXHIBIT AND FINANCIAL STATEMENT SCHEDULES
145
ITEM 16. FORM 10-K SUMMARY
147
SIGNATURES
148
All trademarks, trade names, service marks, and copyrights appearing in this Annual Report on Form 10-K are the property of their respective owners.
Table of Contents
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K for the fiscal year ended March 31, 2025 (this “Annual Report”) contains forward-looking statements that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words “anticipate,” “believe,” “can,” “continue,” “could,” “design,” “estimate,” “expect,” “forecast,” “goal,” “hope,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will” and “would,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Forward-looking statements include statements about:
•
the timing, progress, costs and results of our clinical trials for our product candidates, IMVT-1402 and batoclimab, formerly referred to as IMVT-1401;
•
potential therapeutic benefits and risks in current and future indications and the ability to achieve regulatory approval in licensed jurisdictions;
•
future operating or financial results and cash position;
•
future acquisitions, business strategy and expected capital spending;
•
the timing of meetings with and feedback from regulatory authorities as well as any submission of filings for regulatory approval of our product candidates;
•
the potential advantages and differentiated profile of our product candidates compared to existing therapies for the applicable indications, including potential benefits of IMVT-1402’s product attributes and potential best-in-class profile;
•
our ability to successfully manufacture, or have manufactured, drug product for clinical trials and commercialization;
•
our ability to successfully commercialize our product candidates, if approved;
•
the rate and degree of market acceptance of our product candidates, if approved;
•
the effects of global factors, geopolitical tensions and adverse macroeconomic conditions, on our business, operations and supply chain, including the potential impact on our clinical trial plans and timelines, such as the enrollment, activation and initiation of additional clinical trial sites, and the results of our clinical trials;
•
our expectations regarding the size of the patient populations, opportunity and clinical utility of our product candidates, if approved for commercial use;
•
our estimates of our expenses, ongoing losses, future revenue, capital requirements and needs for or ability to obtain future financing to complete the clinical trials for and commercialize our product candidates;
•
our dependence on and plans to leverage third parties for research and development, clinical trials, manufacturing, and other activities;
•
our ability to maintain intellectual property protection for our product candidates;
•
our ability to identify, acquire or in-license and develop new product candidates;
•
our ability to identify, recruit and retain key personnel;
•
developments and projections relating to our competitors or industry; and
•
future payments of dividends and the availability of cash for payment of dividends.
Table of Contents
You should refer to “